BRPI0414979A - preparação sólida - Google Patents

preparação sólida

Info

Publication number
BRPI0414979A
BRPI0414979A BRPI0414979-3A BRPI0414979A BRPI0414979A BR PI0414979 A BRPI0414979 A BR PI0414979A BR PI0414979 A BRPI0414979 A BR PI0414979A BR PI0414979 A BRPI0414979 A BR PI0414979A
Authority
BR
Brazil
Prior art keywords
solid preparation
insulin
secretagogue
sensitizer
insulin sensitizer
Prior art date
Application number
BRPI0414979-3A
Other languages
English (en)
Inventor
Kazuhiro Doken
Tetsuya Kawano
Hiroyoshi Koyama
Naoru Hamaguchi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34543966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0414979(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BRPI0414979A publication Critical patent/BRPI0414979A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PREPARAçãO SóLIDA". Uma preparação sólida útil como um agente de tratamento do diabete ou semelhante, e excelente nas propriedades de dissolução de um sensibilizador insulínico e um secretagogo insulínico, a qual compreende um sensibilizador insulínico, um secretagogo insulínico e um éster de ácido graxo de polioxietileno sorbitano, é fornecida.
BRPI0414979-3A 2003-10-31 2004-10-21 preparação sólida BRPI0414979A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003371679 2003-10-31
PCT/JP2004/015958 WO2005041962A1 (en) 2003-10-31 2004-10-21 Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester

Publications (1)

Publication Number Publication Date
BRPI0414979A true BRPI0414979A (pt) 2006-11-21

Family

ID=34543966

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414979-3A BRPI0414979A (pt) 2003-10-31 2004-10-21 preparação sólida

Country Status (28)

Country Link
US (1) US7700128B2 (pt)
EP (1) EP1677792B1 (pt)
KR (2) KR20100012105A (pt)
CN (1) CN1874774B (pt)
AR (1) AR046210A1 (pt)
AU (1) AU2004285354B2 (pt)
BR (1) BRPI0414979A (pt)
CA (1) CA2540225C (pt)
CY (1) CY1117176T1 (pt)
DK (1) DK1677792T3 (pt)
ES (1) ES2556244T3 (pt)
GE (1) GEP20084570B (pt)
HR (1) HRP20151447T1 (pt)
HU (1) HUE028576T2 (pt)
IL (1) IL174201A (pt)
JO (1) JO3106B1 (pt)
MA (1) MA28116A1 (pt)
MX (1) MXPA06004639A (pt)
NO (1) NO340294B1 (pt)
NZ (1) NZ546337A (pt)
PE (1) PE20050923A1 (pt)
PL (1) PL1677792T3 (pt)
PT (1) PT1677792E (pt)
RU (1) RU2359661C2 (pt)
SI (1) SI1677792T1 (pt)
TW (1) TWI339586B (pt)
WO (1) WO2005041962A1 (pt)
ZA (1) ZA200602056B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
NZ569071A (en) * 2005-12-22 2011-01-28 Takeda Pharmaceutical Solid preparation containing an insulin sensitizer
CA2656181C (en) 2006-06-27 2011-09-06 Daiichi Sankyo Company, Limited Compressed preparation of compositions comprising olmesartan medoxomil
CN101646420B (zh) * 2007-02-01 2012-11-07 武田药品工业株式会社 包含阿格列汀和吡格列酮的固体制剂
IS8660A (is) * 2007-07-02 2009-01-03 Actavis Group Ptc Ehf. Gliklasíð lyfjasamsetning
WO2009120844A2 (en) * 2008-03-26 2009-10-01 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions comprising insulin sensitizer and insulin secretagogue
WO2010064147A2 (en) 2008-12-04 2010-06-10 Ikfe Gmbh Biomarkers for atherosclerosis
AU2009325962A1 (en) 2008-12-11 2011-07-28 Ikfe Institut Fur Klinische Forschung Und Entwicklung Gmbh Biomarkers for insulin sensitizer drug response
WO2010076655A1 (en) 2008-12-30 2010-07-08 Ikfe Gmbh Biomarkers for adipose tissue activity
EP2382475A2 (en) 2009-01-07 2011-11-02 IKFE GmbH Biomarkers for appetite regulation
WO2010107519A1 (en) * 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
US9675603B2 (en) * 2010-09-21 2017-06-13 Intekrin Therapeutics, Inc. Solid pharmaceutical compositions of ppary modulator
EP2438911A1 (en) 2010-10-08 2012-04-11 LEK Pharmaceuticals d.d. Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil
WO2013034174A1 (en) * 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Solid preparations of pioglitazone and glimepiride
CN104288161A (zh) * 2014-09-19 2015-01-21 四川海思科制药有限公司 一种含吡格列酮格列美脲的药物组合物
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5865213A (ja) * 1981-10-13 1983-04-18 Tokai Kapuseru Kk ｄｌ−２−（４，８，１２−トリメチルトリデシル）−２，５，７，８−テトラメチル−６−クロマニルニコチネ−ト軟カプセル剤
US4620974A (en) * 1983-07-07 1986-11-04 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
JP2764274B2 (ja) * 1988-03-28 1998-06-11 株式会社ミドリ十字 医薬組成物
CA2175494C (en) * 1993-11-03 2000-09-19 Young W. Cho Microparticular pharmaceutical compositions
HU212428B (en) * 1994-05-13 1996-06-28 Egyt Gyogyszervegyeszeti Gyar Process to prepare pharmaceutical compositions containing gemfibrozyl
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
FR2758461A1 (fr) * 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6291495B1 (en) 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
PL337510A1 (en) 1997-06-18 2000-08-28 Smithkline Beecham Plc Treatment of diabetes by means of derivatives of thiazolydinone and sulphonylurea
GB9715295D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715298D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9715306D0 (en) 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
EP1017370B1 (en) * 1997-09-11 2003-10-29 Nycomed Danmark ApS MODIFIED RELEASE MULTIPLE-UNITS COMPOSITIONS OF NON-STEROID ANTI-INFLAMMATORY DRUG SUBSTANCES (NSAIDs)
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
CZ20011629A3 (cs) 1998-11-12 2001-12-12 Smithkline Beecham Plc Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
AU7556800A (en) 1999-10-07 2001-05-10 Tadeka Chemical Industries, Ltd. Amine derivatives
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
WO2001082925A1 (fr) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Antagonistes de l'hormone concentrant la melanine
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
WO2001087834A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
EP1437351A4 (en) 2001-10-19 2005-06-01 Takeda Pharmaceutical AMINE DERIVATIVE
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2003281181A1 (en) 2002-07-11 2004-02-02 Takeda Pharmaceutical Company Limited Process for producing coated preparation
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
US20040147564A1 (en) 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
CA2514539C (en) 2003-01-29 2012-03-06 Takeda Pharmaceutical Company Limited Process for producing coated preparation
FR2853831A1 (fr) * 2003-03-05 2004-10-22 Usv Ltd Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation

Also Published As

Publication number Publication date
RU2006118786A (ru) 2007-12-10
EP1677792A1 (en) 2006-07-12
TW200524641A (en) 2005-08-01
HUE028576T2 (en) 2016-12-28
JO3106B1 (ar) 2017-09-20
AU2004285354A1 (en) 2005-05-12
MXPA06004639A (es) 2006-06-27
NZ546337A (en) 2009-03-31
KR20100012105A (ko) 2010-02-05
MA28116A1 (fr) 2006-08-01
IL174201A0 (en) 2006-08-01
WO2005041962A1 (en) 2005-05-12
AR046210A1 (es) 2005-11-30
TWI339586B (en) 2011-04-01
PT1677792E (pt) 2016-02-09
HRP20151447T1 (hr) 2016-02-12
CN1874774B (zh) 2011-04-13
CA2540225C (en) 2012-03-06
CY1117176T1 (el) 2017-04-05
US20060223870A1 (en) 2006-10-05
SI1677792T1 (sl) 2016-02-29
DK1677792T3 (en) 2015-12-14
GEP20084570B (en) 2008-12-25
PE20050923A1 (es) 2005-12-26
PL1677792T3 (pl) 2016-05-31
KR100952090B1 (ko) 2010-04-13
CN1874774A (zh) 2006-12-06
IL174201A (en) 2011-04-28
ES2556244T3 (es) 2016-01-14
AU2004285354B2 (en) 2009-09-17
EP1677792B1 (en) 2015-11-18
RU2359661C2 (ru) 2009-06-27
CA2540225A1 (en) 2005-05-12
NO20062515L (no) 2006-07-31
NO340294B1 (no) 2017-03-27
KR20060061383A (ko) 2006-06-07
ZA200602056B (en) 2007-05-30
US7700128B2 (en) 2010-04-20

Similar Documents

Publication Publication Date Title
BRPI0414979A (pt) preparação sólida
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
BR0110573A (pt) Composto, composição farmacêutica que compreende esse composto, processo para a preparação de uma composição farmacêutica, utilização do composto e processo para o tratamento profilático ou terapêutico e para a preparação do composto
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
EA200200431A1 (ru) Фармацевтические композиции, обеспечивающие повышенные концентрации лекарства
TR200001892T2 (tr) Monomer cinsi ensülin analogları ve bunların kullanımı.
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
DE60111570D1 (de) Isoindolin-1-on als glukokinaseaktivatoren
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
WO2002028999A3 (en) Gene expression profiles in granulocytic cells
SE0001899D0 (sv) New compounds
NO20014415D0 (no) Medisinske preparater til behandling av <alfa>-galaktosidase- A-defisiens
DK1572127T3 (da) Enzymbehandling af fødevarer til cøliaki
SE9702860D0 (sv) New use
WO2005043967A8 (en) Z-axis assembly of medical device programmer
EA200501819A1 (ru) Способы и фармацевтические композиции для достоверного достижения приемлемых уровней тестостерона в сыворотке
DE60215866D1 (de) Medikament, enthaltend cyanidin-3-glykosid als wirkstoff gegen fettsucht und diabetes
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
EA200401111A1 (ru) Биполярные соли транс-каротиноидов и их применение
ATE253820T1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
NO20050247L (no) Lavmolekylaert oversulfatert polysakkarid
EE05124B1 (et) Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine
ATE256392T1 (de) Verwendung von polyaminosäurederivate als konservierungsmittel
EA200100802A1 (ru) Применение тианептина при приготовлении лекарственных средств, предназначенных для лечения нейродегенеративных патологий
BR0202759A (pt) Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/4439, 31/64, 47/26; A61P 3/10

Ipc: A61K 31/4439 (2011.01), A61K 31/64 (2011.01), A61K

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.